Back to Trades
Total Value
$686.0K
Filing Date
Mar 23, 2026
1 transactions
Trade Summary
On Jan 27, 2026, te Boekhorst Paul Francis Olivier, President and CEO, Director, reported $686.0K of IMMUCELL CORP /DE/ (ICCC) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $6.26. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- IMMUCELL CORP /DE/
- Ticker Symbol
- ICCC
- CIK
- 0000811641
Insider Information
- Role
- President and CEO, Director
- Location
- PORTLAND, ME
Filing Details
- Filing Date
- Mar 23, 2026
- Transaction Date
- Jan 27, 2026
- Accession Number
- 0001437749-26-009312
- Form Type
- 4
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jan 27, 2026 | ICCC derivative | 109,500 | $6.26 | Grant/Award | $686.0K |
Want live alerts when te Boekhorst Paul Francis Olivier trades again?
Download Insider Trades to track ICCC, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)This amendment amends the previously reported transaction effective on 1/27/2026 to disclose the correct number of shares included in the option award.
- (F2)Option grant made to Mr. te Boekhorst in connection with his employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as nonqualified stock option. One hundred percent of the stock option will vest when the Issuer's net operating income for four consecutive calendar quarters equals or exceeds 300% of the Issuer's audited net operating income for its 2025 fiscal year.